Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment / Swan, D., O'Dwyer, M.e., Cahill, M., Krawczyk, J., Mykytiv, V., Quinn, J., Henderson, R., Mcellistrim, C., Hernando, A., Parker, I., Nolan, M., Lenihan, E., Szegezdi, E., Naicker, S.d., Lynch, K., Natoni, A., Ryan, A., Murphy, P.. - In: BLOOD. - ISSN 0006-4971. - 138:Supplement 1(2021), pp. 2756-2756. [10.1182/blood-2021-145530]
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
Natoni, AInvestigation
;
2021
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
